[Postprandial hyperglycemia. Cardiovascular risks and new therapeutic strategies].
In contrast to fasting glucose, postprandial hyperglycemia in type 2-diabetes has been a relatively neglected area. However, postprandial glucose spikes contribute significantly to overall glycemic control and are strongly correlated with cardiovascular morbidity and mortality (as opposed to fasting glucose). Here we review extant data implicating postprandial hyperglycemia as a tangible target for novel antidiabetic drugs with improved potential to curb not only deleterious glucose excursions, but also the macrovascular complications associated with them.
Sjöholm
A
A
Karolinska sjukhuset, Stockholm. ake@enk.ks.se
D001786:Blood Glucose / Q000032:analysis; D002318:Cardiovascular Diseases / Q000209:etiology* / Q000517:prevention & control; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000150:complications / Q000628:therapy; D003925:Diabetic Angiopathies / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D006943:Hyperglycemia / Q000150:complications / Q000188:drug therapy / Q000209:etiology*; D007004:Hypoglycemic Agents / Q000008:administration & dosage; D019518:Postprandial Period; D012307:Risk Factors
D001786:Blood Glucose; D007004:Hypoglycemic Agents